In8bio, Inc (INAB)

$0.23

+0.01

(+3.08%)▲

Market is closed - opens 7 PM, 16 Oct 2024

Performance

  • $0.23
    $0.24
    $0.23
    downward going graph

    2.13%

    Downside

    Day's Volatility :6.6%

    Upside

    4.56%

    downward going graph
  • $0.22
    $2.48
    $0.23
    downward going graph

    5.65%

    Downside

    52 Weeks Volatility :91.25%

    Upside

    90.73%

    downward going graph

Returns

PeriodIn8bio, IncIndex (Russel 2000)
3 Months
-73.26%
0.0%
6 Months
-77.75%
0.0%
1 Year
-74.74%
0.0%
3 Years
-90.34%
-21.9%

Highlights

Market Capitalization
16.3M
Book Value
$0.29
Earnings Per Share (EPS)
-0.82
Wall Street Target Price
7.38
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-77.64%
Return On Equity TTM
-180.45%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-30.6M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.56
EPS Estimate Next Year
-0.3
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for In8bio, Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3108.7%

Current $0.23
Target $7.38

Technicals Summary

Sell

Neutral

Buy

In8bio, Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
In8bio, Inc
In8bio, Inc
-25.7%
-77.75%
-74.74%
-90.34%
-90.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.04%
12.88%
20.22%
83.33%
233.83%
Novo Nordisk A/s
Novo Nordisk A/s
-12.51%
-3.33%
18.42%
134.08%
356.57%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
4.79%
91.82%
69.4%
35.85%
250.43%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.94%
22.01%
29.63%
166.72%
175.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
In8bio, Inc
In8bio, Inc
NA
NA
NA
-0.56
-1.8
-0.78
NA
0.29
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.87
26.87
1.38
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.84
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.43
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
In8bio, Inc
In8bio, Inc
Buy
$16.3M
-90.34%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.9B
233.83%
26.87
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$535.2B
356.57%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
250.43%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.1B
175.25%
32.84
-4.74%

Insights on In8bio, Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.5% return, outperforming this stock by 144.2%

Institutional Holdings

  • AIGH Capital Management, LLC

    4.55%

  • Vanguard Group Inc

    3.04%

  • Ensign Peak Advisors Inc

    2.39%

  • Alyeska Investment Group, L.P.

    1.37%

  • Sigma Planning Corp

    1.28%

  • 683 Capital Management LLC

    1.26%

Company Information

in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.

Organization
In8bio, Inc
Employees
39
CEO
Mr. Tai-Wei Ho
Industry
Health Technology

Discover More

FAQs